CA2550010A1 - Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b - Google Patents

Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b Download PDF

Info

Publication number
CA2550010A1
CA2550010A1 CA002550010A CA2550010A CA2550010A1 CA 2550010 A1 CA2550010 A1 CA 2550010A1 CA 002550010 A CA002550010 A CA 002550010A CA 2550010 A CA2550010 A CA 2550010A CA 2550010 A1 CA2550010 A1 CA 2550010A1
Authority
CA
Canada
Prior art keywords
disorder
carbons
selective
lower alkyl
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002550010A
Other languages
English (en)
French (fr)
Inventor
Jayasree Vasudevan
Rong Yang
Liming Wang
Xiaoxia Liu
Kwok Yin Tsang
Ling Li
Janet A. Takeuchi
Thong Vu
Richard L. Beard
Smita Bhat
Roshantha A. Chandraratna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2550010A1 publication Critical patent/CA2550010A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002550010A 2003-12-17 2004-12-13 Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b Abandoned CA2550010A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53060103P 2003-12-17 2003-12-17
US60/530,601 2003-12-17
PCT/US2004/041889 WO2005058301A1 (en) 2003-12-17 2004-12-13 Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b

Publications (1)

Publication Number Publication Date
CA2550010A1 true CA2550010A1 (en) 2005-06-30

Family

ID=34700149

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002550010A Abandoned CA2550010A1 (en) 2003-12-17 2004-12-13 Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b

Country Status (5)

Country Link
US (1) US7468391B2 (enExample)
EP (1) EP1696899A1 (enExample)
JP (1) JP2007515433A (enExample)
CA (1) CA2550010A1 (enExample)
WO (1) WO2005058301A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019113693A1 (en) * 2017-12-12 2019-06-20 Queen's University At Kingston Compounds and methods for inhibiting cyp26 enzymes

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
EP1888123B1 (en) 2005-06-08 2013-01-09 Janssen Biotech, Inc. A cellular therapy for ocular degeneration
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
KR101057546B1 (ko) * 2007-06-05 2011-08-17 주식회사 엘지화학 광학 이방성 화합물 및 이를 포함하는 수지 조성물
CN103664637B (zh) 2007-06-29 2016-02-03 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的炔基苯基衍生化合物
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
US9096832B2 (en) 2007-07-31 2015-08-04 Lifescan, Inc. Differentiation of human embryonic stem cells
JP2009108036A (ja) * 2007-09-28 2009-05-21 Fujifilm Corp 新規アセチレン化合物、その製造方法、それを構成単位として含むポリマー、該化合物及び／又は該ポリマーを含む組成物、該組成物を硬化させてなる硬化物
ATE523585T1 (de) 2007-11-27 2011-09-15 Lifescan Inc Differenzierung menschlicher embryonaler stammzellen
CA2959401C (en) 2008-02-21 2021-12-07 Centocor Ortho Biotech Inc. Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
EP2318516A1 (en) * 2008-06-30 2011-05-11 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
KR101651661B1 (ko) 2008-06-30 2016-08-26 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 분화
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
CN102272291B (zh) * 2008-10-31 2018-01-16 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
MX2011004563A (es) 2008-10-31 2011-06-01 Centocor Ortho Biotech Inc Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico.
PL2366021T3 (pl) 2008-11-20 2017-12-29 Janssen Biotech, Inc. Hodowla pluripotencjalnych komórek macierzystych na mikronośnikach
PL2366022T3 (pl) 2008-11-20 2016-11-30 Sposoby i kompozycje do przyłączania i hodowli komórek na podłożach planarnych
ES2693088T3 (es) * 2009-07-20 2018-12-07 Janssen Biotech, Inc. Diferenciación de células madre embriónicas humanas
AU2010276402B2 (en) 2009-07-20 2014-07-03 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
KR20170118969A (ko) 2009-07-20 2017-10-25 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
US20120190716A1 (en) * 2009-08-05 2012-07-26 Oehlen Lambertus J W M Methods and uses of cytochrome p450 inhibitors
AU2010333839C1 (en) * 2009-12-23 2016-07-21 Janssen Biotech Inc. Differentiation of human embryonic stem cells
MX339669B (es) 2009-12-23 2016-06-02 Janssen Biotech Inc Diferenciacion de celulas madres embrionarias humanas.
CN107189979B (zh) * 2010-03-01 2021-05-04 詹森生物科技公司 纯化衍生自多能干细胞的细胞的方法
KR101986176B1 (ko) 2010-05-12 2019-06-05 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
WO2012030539A2 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
AU2011296381B2 (en) 2010-08-31 2016-03-31 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
WO2012030540A2 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US9248120B2 (en) 2011-08-23 2016-02-02 The Board Of Trustees Of The Leland Stanford Junior University Reversing intestinal inflammation by inhibiting retinoic acid metabolism
EP2910549A1 (en) 2011-09-15 2015-08-26 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University 1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalene derivatives useful as rxr modulators for treating alzheimer's disease and cancer
US9388386B2 (en) 2011-12-22 2016-07-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
CA2866590A1 (en) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
WO2013184888A1 (en) 2012-06-08 2013-12-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
RU2684215C2 (ru) 2012-12-31 2019-04-04 Янссен Байотек, Инк. Способ получения панкреатических эндокринных клеток (варианты) и способ увеличения выхода бета-клеток
WO2014105543A1 (en) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
RU2687379C2 (ru) 2012-12-31 2019-05-13 Янссен Байотек, Инк. Суспендирование и кластеризация плюрипотентных клеток человека с целью их дифференцировки в панкреатические эндокринные клетки
US10328040B2 (en) 2014-01-17 2019-06-25 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic methods
JP6588969B2 (ja) 2014-05-16 2019-10-09 ヤンセン バイオテツク，インコーポレーテツド 膵内分泌細胞内のｍａｆａ発現を強化するための小分子の使用
US10759762B2 (en) * 2014-10-10 2020-09-01 High Force Research Limited Fluorescent synthetic retinoids
CN105481723B (zh) * 2015-04-29 2017-08-25 中国农业大学 一种非均相催化的烷基/苄基/芳基脲类化合物的制备方法
PL3380086T3 (pl) 2015-11-25 2022-02-21 Io Therapeutics, Inc. Oporne na cyp26 agonisty selektywne względem rar-alfa w leczeniu nowotworu
CN107176945B (zh) * 2016-03-11 2021-06-08 中国科学院上海有机化学研究所 一种视黄酸类化合物、其制备方法、中间体及应用
JP6705911B2 (ja) 2016-04-14 2020-06-03 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞の中腸内胚葉細胞への分化
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
WO2019121143A1 (en) 2017-12-20 2019-06-27 Basf Se Substituted cyclopropyl derivatives
TW202045491A (zh) * 2019-02-20 2020-12-16 日商第一三共股份有限公司 唑衍生物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599967A (en) 1994-12-29 1997-02-04 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity
US5952345A (en) 1995-09-01 1999-09-14 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5723666A (en) 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US7537919B2 (en) * 1999-12-16 2009-05-26 Cytochroma Inc. Cytochrome P450RAI-2 and related proteins
WO2002048334A2 (en) 2000-12-15 2002-06-20 Cytochroma Inc. P450rai-2 (p450 cytochrome 26b), encoding nucleic acid molecules and methods and uses thereof
US6380256B1 (en) * 2000-08-29 2002-04-30 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6387951B1 (en) * 2000-08-29 2002-05-14 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6303785B1 (en) 2000-08-29 2001-10-16 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6252090B1 (en) * 2000-08-29 2001-06-26 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en) * 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US20030166932A1 (en) 2002-01-04 2003-09-04 Beard Richard L. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
GB0204735D0 (en) * 2002-02-28 2002-04-17 Inpharmatica Ltd Protein
BRPI0412424A (pt) 2003-07-10 2006-09-05 Osi Pharm Inc composto, composição farmacêutica, método para tratar doenças dermatológicas ou cancerosas em um mamìfero, composição, e, método para tratar doenças relacionadas com a pele ou cancerosas
US7226951B2 (en) * 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019113693A1 (en) * 2017-12-12 2019-06-20 Queen's University At Kingston Compounds and methods for inhibiting cyp26 enzymes
US11795148B2 (en) 2017-12-12 2023-10-24 Queen's University At Kingston Compounds and methods for inhibiting CYP26 enzymes
US12297173B2 (en) 2017-12-12 2025-05-13 Queen's University At Kingston Compounds and methods for inhibiting CYP26 enzymes

Also Published As

Publication number Publication date
US7468391B2 (en) 2008-12-23
WO2005058301A1 (en) 2005-06-30
EP1696899A1 (en) 2006-09-06
US20050187298A1 (en) 2005-08-25
JP2007515433A (ja) 2007-06-14

Similar Documents

Publication Publication Date Title
WO2005058301A1 (en) Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b
CA2550123A1 (en) Compounds having selective cytochrome p450rai-1 or selective cytochrome p450rai-2 inhibitory activity and methods of obtaining the same
DE69103636T2 (de) Biaromatische verbindungen und ihre anwendung in menschen- und tierheilkunde und in der kosmetik.
FI88793B (fi) Foerfarande foer framstaellning av farmakologiskt aktiva fenylnaftalenderivat
US6495552B2 (en) Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
EP3181132A1 (en) Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin penetration rates
AU637756B2 (en) Isoprenoid phospholipase a2 inhibitors and preparations comprising same
JPH06501458A (ja) レチノイドとステロールを組合せて含有する医薬又は化粧料組成物
KR100263581B1 (ko) 이고리형 방향족 화합물 함유 약학 및 미용 조성물
DE60116642T2 (de) Verbindungen mit cytochrom p450ra1 hemmenden aktivität
HUP9903834A2 (hu) Apoptózist kiváltó adamantilszármazékok és alkalmazásuk rákellenes szerként
AU2001286478A1 (en) Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome P450RAI
JP2003521513A (ja) 抗癌剤としてのアダマンチル誘導体
EP1281399A2 (en) Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production
DE60005689T2 (de) Neue aminobenzophenone
US6359135B1 (en) Compounds having activity as inhibitors of cytochrome P450RAI
JPH09504553A (ja) ５α−レダクターゼ阻害薬としての７−置換−４−アザ−ステロイド誘導体
JP7073384B2 (ja) 化合物及び使用方法
JP2001502722A (ja) 新規なヘテロエチニレン化合物およびそれらを含有する薬理学的および化粧品組成物
US6380256B1 (en) Compounds having activity as inhibitors of cytochrome P450RAI
EP2072494B1 (en) Cosmetic and pharmaceutical compositions
JP2000506546A (ja) アルキレンジアミン二酢酸又はアルキレンジアミン三酢酸から誘導された新規化合物とその製造方法並びに化粧料及び製薬組成物におけるその用途と該化合物を含む組成物
WO2018022797A1 (en) Dermatological formulations of 2-(2-ethoxy-2-oxoethyl)(methyl)amino-2-oxoethyl 5-(tetradecyloxy)furan-2-carboxylate
JP2018516971A (ja) ベータナフトイソフラボン、これを含有する組成物及びその使用
JPH10512275A (ja) ４−アザ−１９−ノルアンドロスタン誘導体

Legal Events

Date Code Title Description
FZDE Discontinued